404 related articles for article (PubMed ID: 9118928)
1. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis.
Cox LA
Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1413-29. PubMed ID: 9118928
[TBL] [Abstract][Full Text] [Related]
2. Reassessing benzene cancer risks using internal doses.
Cox LA; Ricci PF
Risk Anal; 1992 Sep; 12(3):401-10. PubMed ID: 1410709
[TBL] [Abstract][Full Text] [Related]
3. Metabolite-based internal doses used in a risk assessment of benzene.
Bailer AJ; Hoel DG
Environ Health Perspect; 1989 Jul; 82():177-84. PubMed ID: 2792038
[TBL] [Abstract][Full Text] [Related]
4. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.
Cronin WJ; Oswald EJ; Shelley ML; Fisher JW; Flemming CD
Risk Anal; 1995 Oct; 15(5):555-65. PubMed ID: 7501875
[TBL] [Abstract][Full Text] [Related]
5. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
6. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach.
Yokley K; Tran HT; Pekari K; Rappaport S; Riihimaki V; Rothman N; Waidyanatha S; Schlosser PM
Risk Anal; 2006 Aug; 26(4):925-43. PubMed ID: 16948686
[TBL] [Abstract][Full Text] [Related]
7. The shape of low-concentration dose-response functions for benzene: implications for human health risk assessment.
Cox LA; Ketelslegers HB; Lewis RJ
Crit Rev Toxicol; 2021 Feb; 51(2):95-116. PubMed ID: 33853483
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method.
Thomas RS; Lytle WE; Keefe TJ; Constan AA; Yang RS
Fundam Appl Toxicol; 1996 May; 31(1):19-28. PubMed ID: 8998950
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the theoretical foundations of the exponential and beta-Poisson dose-response models to quantify parameter uncertainty using Markov Chain Monte Carlo.
Schmidt PJ; Pintar KD; Fazil AM; Topp E
Risk Anal; 2013 Sep; 33(9):1677-93. PubMed ID: 23311599
[TBL] [Abstract][Full Text] [Related]
10. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
Marino DJ; Starr TB
Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
[TBL] [Abstract][Full Text] [Related]
11. Benzene dosimetry in experimental animals: relevance for risk assessment.
Henderson RF; Sabourin PJ; Medinsky MA; Birnbaum LS; Lucier GL
Prog Clin Biol Res; 1992; 374():93-105. PubMed ID: 1620720
[TBL] [Abstract][Full Text] [Related]
12. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
13. Human respiratory tract cancer risks of inhaled formaldehyde: dose-response predictions derived from biologically-motivated computational modeling of a combined rodent and human dataset.
Conolly RB; Kimbell JS; Janszen D; Schlosser PM; Kalisak D; Preston J; Miller FJ
Toxicol Sci; 2004 Nov; 82(1):279-96. PubMed ID: 15254341
[TBL] [Abstract][Full Text] [Related]
14. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
[TBL] [Abstract][Full Text] [Related]
15. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
[TBL] [Abstract][Full Text] [Related]
16. Towards quantitative uncertainty assessment for cancer risks: central estimates and probability distributions of risk in dose-response modeling.
Kopylev L; Chen C; White P
Regul Toxicol Pharmacol; 2007 Dec; 49(3):203-7. PubMed ID: 17905499
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
Krishnan K; Johanson G
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
[TBL] [Abstract][Full Text] [Related]
18. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification.
Chou WC; Lin Z
Environ Int; 2019 Aug; 129():408-422. PubMed ID: 31152982
[TBL] [Abstract][Full Text] [Related]
19. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.
El-Masri HA; Bell DA; Portier CJ
Toxicol Appl Pharmacol; 1999 Aug; 158(3):221-30. PubMed ID: 10438655
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane.
Jonsson F; Johanson G
Toxicol Appl Pharmacol; 2001 Jul; 174(2):99-112. PubMed ID: 11446825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
